Inflexion portfolio receives multiple accolades at the BVCA Vision Series

Inflexion is pleased to announce that four of its portfolio companies have been recognised for exceptional performance at the BVCA’s Vision 2022 Series, an accolade awarded to only 15 private equity-backed businesses in the UK this year. K2 Partnering Solutions, Rosemont Pharmaceuticals, Sparta Global and Chambers and Partners were all named, with Chambers additionally recognised as the best mid-sized company, meaning the firm received two distinct awards.

The BVCA’s Vision 2022 Series recognises the best teams backed by private equity and venture capital, with judging criteria including growth, competitiveness, innovation and ESG factors over the course of 2021. Vision 2022 represents an evolution of BVCA’s Management Team Awards, which existed for over a decade, and briefly evolved into “Adapting with Purpose” in response to the COVID-19 crisis.

The four businesses recognised reflect the positive value created through hands-on collaboration with Inflexion’s Buyout Fund, dedicated minority investment Partnership Capital Fund and lower mid-market Enterprise Fund.